EUVIMEDEUVIMED entdecken
Crossref

Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals

Lena Sannemann, Claudia Bartels, Frederic Brosseron, Katharina Buerger, Klaus Fliessbach, Silka Dawn Freiesleben, Ingo Frommann, Wenzel Glanz, Michael T Heneka, Daniel Janowitz, Ingo Kilimann, Luca Kleineidam und 21 weitere

Journal of Alzheimer's Disease · 25.06.2024 · 100 (1) · 193-205

DOI: 10.3233/jad-231335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 25.06.2024. Verfasst von Lena Sannemann und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Cognitive Dysfunction, Biomarkers, Peptide Fragments. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The NIA-AA Research Framework on Alzheimer’s disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).

Objective

To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.

Methods

We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.

Results

We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.

Conclusions

The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesCognitive DysfunctionBiomarkersPeptide FragmentsNeuropsychological TestsAlzheimer DiseaseHumansMaleFemaleAgedMiddle AgedCohort StudiesAged, 80 and overCluster Analysis

Stichwörter der Autor:innen

Alzheimer’s diseaseAlzheimer’s disease continuumNIA-AA stage 2amyloidcerebrospinal fluid biomarkersneuropsychiatric symptomspreclinical Alzheimer’s diseasesubjective cognitive decline

Substanzen

Amyloid beta-PeptidesBiomarkersPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
  • Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Göttingen, Germany.
  • German Center for Neurodegenerative Diseases - DZNE, Bonn, Germany.
  • German Center for Neurodegenerative Diseases - DZNE, Munich, Germany.
  • Institute for Stroke and Dementia Research - ISD, University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Bonn, Germany.

Zitieren

APA

Sannemann, L., Bartels, C., Brosseron, F., Buerger, K., Fliessbach, K., Freiesleben, S. D., Frommann, I., Glanz, W., Heneka, M. T., Janowitz, D., Kilimann, I., Kleineidam, L., Lammerding, D., Laske, C., Munk, M. H. J., Perneczky, R., Peters, O., Priller, J., Rauchmann, B. S., …, & DELCODE Study Group (2024). Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals. Journal of Alzheimer's Disease, 100(1), 193-205. https://doi.org/10.3233/jad-231335

Vancouver

Sannemann L, Bartels C, Brosseron F, Buerger K, Fliessbach K, Freiesleben SD, et al. Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals. Journal of Alzheimer's Disease. 2024;100(1):193-205. doi:10.3233/jad-231335

BibTeX
@article{Sannemann2024,
  author = {Sannemann, Lena and Bartels, Claudia and Brosseron, Frederic and Buerger, Katharina and Fliessbach, Klaus and Freiesleben, Silka Dawn and Frommann, Ingo and Glanz, Wenzel and Heneka, Michael T and Janowitz, Daniel and Kilimann, Ingo and Kleineidam, Luca and Lammerding, Dominik and Laske, Christoph and Munk, Matthias H J and Perneczky, Robert and Peters, Oliver and Priller, Josef and Rauchmann, Boris-Stephan and Rostamzadeh, Ayda and Roy-Kluth, Nina and Schild, Ann-Katrin and Schneider, Anja and Schneider, Luisa-Sophie and Spottke, Annika and Spruth, Eike Jakob and Teipel, Stefan and Wagner, Michael and Wiltfang, Jens and Wolfsgruber, Steffen and Duezel, Emrah and Jessen, Frank and DELCODE Study Group, DELCODE Study Group},
  title = {Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals},
  journal = {Journal of Alzheimer's Disease},
  year = {2024},
  volume = {100},
  number = {1},
  pages = {193--205},
  doi = {10.3233/jad-231335}
}
Kostenlos starten →